Prelude Therapeutics nabs $60M series B, gains biopharma veteran as CMO

fiercebiotech | June 12, 2019

Prelude Therapeutics has completed a $60 million series B round, boosting its total raised to $95 million as it looks to deepen its cancer work into the clinic. The Wilmington, Delaware-based biotech also announced that David Mauro, M.D., Ph.D., recently joined as its new chief medical officer, coming from the same position at Checkmate Pharmaceuticals. He’s also served stints at Bristol-Myers Squibb, Merck and Advaxis. The cash boost and the new CMO will help with the startup’s work on its discovery and development of small molecule drugs that target key drivers of cancer cell growth, survival and resistance. Since 2016, it’s been working specifically on protein arginine methyltransferase 5 (PRMT5), a member of the arginine methyltransferase family. The $60 million will go toward advancing Prelude’s PRMT5 inhibitor, PRT543, through proof of concept clinical studies. PRT543 is currently in a parallel dose escalation phase 1 clinical trial for solid tumors, myeloid malignancies and lymphomas. The company’s also looking beyond PRMT5, setting up several drug discovery programs and compounds from its early-stage programs that will enter preclinical development in the second half of 2019 with a potential IND filing in 2020, it said in a statement. “We are very appreciative of the continued support of our current investors, who have been integral to the founding of Prelude and the creation of our growing pipeline,” said Kris Vaddi, Ph.D., founder and CEO of Prelude.

Spotlight

Dr Mariechel Navarro, Director, ISAAA Global Knowledge Center on Crop Biotechnology, provides the latest information about her project which seeks to better understand who adopts GM/biotech crops

Spotlight

Dr Mariechel Navarro, Director, ISAAA Global Knowledge Center on Crop Biotechnology, provides the latest information about her project which seeks to better understand who adopts GM/biotech crops

Related News

INDUSTRIAL IMPACT

BeiGene Announces Launch of Bioisland Innovation Center

BeiGene | December 27, 2021

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced the official launch of the BeiGene Bioisland Innovation Center in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations. The BIC is an innovator-centric incubator built on BeiGene’s goal of supporting exploration of new paths to meet patient needs around the world. “Over a decade ago, we started BeiGene’s journey by following the science and have grown to be a global biotechnology company with capabilities across the full value chain. With the BIC, we are supporting entrepreneurs with similar purpose and vision of delivering innovation that will benefit more patients worldwide. We expect the center will also contribute to our innovation pipeline,” John V. Oyler, Co-Founder, Chairman and CEO of BeiGene “Science and innovation are BeiGene’s core strengths. We are committed to supporting entrepreneurs incubate bold, new ideas into impactful programs that will create value for patients and benefit patients globally,” added Xiaodong Wang, M.D., Co-Founder of BeiGene, Chairman of the Company’s Scientific Advisory Committee. “With our scientific research, unique clinical development capabilities, and footprint, BeiGene is well positioned to explore new paths of innovation and support new talents in the booming biotechnology hub of Guangzhou’s Greater Bay Area.” Innovator-Centric Incubator to Accelerate Growth and Possibilities The BIC is located in the Guangdong-Hong Kong-Macau Greater Bay Area, an emerging global biotechnology hub, and will feature a comprehensive research infrastructure and professional management team. The incubator will be equipped with state-of-the-art laboratory infrastructure and comprehensive research capabilities that enable scientists and entrepreneurs to get their ideas off the ground. In addition, scientists and entrepreneurs at the BIC will have potential access to support from BeiGene on full industry value chain integration. The comprehensive, advanced technology platform at the BIC will allow innovators more autonomy in development, and integrated services to position them for growth. “The BIC is focused on cultivating entrepreneurship for new biotech companies with a passion for transformational medicines, diagnostics and medical devices that can help address unmet needs, and advancing breakthrough innovations from early discovery to being accessed by patients all over the world,” said Jonathan Liu, Chief Executive of Bioisland Initiative and Chairman of the Board of BeiGene Biologics Co., Ltd. Dr. H. Fai Poon. CEO of Zhongshan Quacell Biotechnology Co., Ltd., which is part of the innovation center, commented, "We share the same beliefs of the model and concept of the BeiGene Bioisland Innovation Center. This kind of international collaboration not only accelerates technical innovation for small and medium-sized enterprises, but also provides suitable platforms and resources to commercialize these innovations. For Quacell, which also has the 'innovative DNA', to be part of the BIC provides the opportunity to communicate and cooperate with many innovative companies in different fields around the world. We look forward to creating a common path for each other's future research and development. And we believe that this path leads to infinite possibilities to upgrade and even revolutionize the industry." About BeiGene BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 8,000 colleagues across five continents.

Read More

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

Business Wire | September 08, 2020

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (“AMR”), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents, and medical devices, including in-vitro diagnostics.

Read More

Moleculin Announces Discovery of Significant In Vitro Activity Against SARS-CoV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repeatedly demonstrated a therapeutic index of greater than 10, which is considered by our team to be an industry-standard commercialization threshold for in vitro performance of antiviral drugs. Walter Klemp, Chairman and CEO of Moleculin, stated, "While we continue to see encouraging progress with WP1122 in preparation for clinical trials for the potential treatment of COVID-19, we have also continued our antiviral drug discovery program to expand the range of potential therapies. Our efforts led to a new discovery that we believe can be a game-changer. WP1096 and its close analog, WP1097, are structurally slightly different agents within the WP1122 portfolio. However, small structural changes unexpectedly resulted in high levels of antiviral activity and potentially a unique mode of action.

Read More